Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
n decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
961
-
962
-
963
-
964
-
965
Decreased myofibroblasts in the peritumoral region and high expression of MMP-7 in Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i><sup><i>f/f</i></sup> mice.
Published 2023“…Scale bar = 50 μm. (D) Microarray analysis of Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i><sup><i>f/f</i></sup> and control mice (N = 4 for each cohort). …”
-
966
-
967
-
968
-
969
-
970
-
971
-
972
-
973
-
974
-
975
-
976
The apparent Ca<sup>2+</sup> affinity of release is decreased by hydrophobic mutations.
Published 2020“…The significant rightward shift in the curve (EC50, non overlapping confidence intervals) indicates a decrease in the apparent Ca<sup>2+</sup> affinity of neurotransmitter release.…”
-
977
-
978
-
979
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
980